FINWIRES · TerminalLIVE
FINWIRES

日立の2025年度純利益は30%急増

By

-- 日立製作所(東証:6501)の親会社株主に帰属する純利益は、2025年度において前年同期の6,157億円から30%増の8,023億円に急増した。 電力・再生可能エネルギー企業向けシステムを提供する同社の1株当たり純利益は、前年同期の133.72円から176.63円に増加した。これは月曜日に東京証券取引所に提出された書類で明らかになった。 3月31日終了の通期売上高は、前年同期の9兆7,830億円から8%増の10兆6,000億円となった。 日立製作所は別途開示した書類の中で、業績およびその他の要因に基づき、年末配当を1株当たり27円とする計画を発表した。 総額約1,215億円の配当金は、5月に取締役会で最終決定され、6月4日に支払われる予定です。 2026年度の株主に帰属する純利益は8,500億円、売上高は11兆1,000億円を見込んでいます。 日立は、当期の中間配当として1株当たり28円を支払う予定です。

Related Articles

Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

$HKG:2315
Oil & Energy

Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions

Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Research

Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target

Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GPCR